Clinical Trial: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease

U.S., Nov. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07246941) titled 'A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease' on Nov. 19.

Brief Summary: This is a first-in-human (FIH) study of RG6496 that will assess the safety and tolerability of single-ascending doses of RG6496 administered to huntington's disease gene expansion carriers (HDGECs). The study consists of two parts: Part 1 [single-ascending dose] followed by Part 2 [open-label extension (OLE)].

Study Start Date: Nov. 19

Study Type: INTERVENTIONAL

Condition: Huntington's Disease

Intervention: DRUG: RG6496

RG6496 will be administered as per the schedule specified in t...